GMED

AUDUBON, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the second quarter ended June 30, 2026 after the market close on Thursday, August 6, 2026. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical’s website at https://www.investors.globusmedical.com/news-events/events-webcasts. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The audio archive will be available after the call on the Investors page of the Globus Medical website. About Globus Medical, Inc.Globus Medical, Inc. is a leading global musculoskeletal company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com. Safe Harbor StatementsAll statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with health epidemics, pandemics and similar outbreaks, factors affecting our qua...

Intuitive Surgical ISRG is set to release second-quarter results on July 16. The Zacks Consensus Estimate for sales is pegged at $2.81 billion, indicating year-over-year growth of 15%, and the same for earnings per share (EPS) implies an improvement of 13.2% to $2.48. The estimate for EPS has remained stable over the past seven days. In the last reported quarter, Intuitive Surgical delivered an earnings surprise of 20.19%. The company’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.82%. Although ISRG’s top and bottom-line figures are likely to reflect strong growth during the second quarter, its shares have underperformed the Zacks Medical - Instrument industry as well as other robotic-surgery device makers — Stryker SYK, Zimmer Biomet ZBH, Globus Medical GMED and Stereotaxis STXS — so far this year. The stock has declined 27.4%, its industry has dipped 14.2%, and the S&P 500 Index has gained 9.5% in the same period. The share prices of SYK, ZBH, GMED and STXS have decreased 6.9%, 0.8%, 12.2% and 24.4%, respectively. YTD Price Performance Image Source: Zacks Investment Research While Stryker commercializes its Mako robotic system for orthopedic joint replacements, Zimmer Biomet has ROSA system, which is available for orthopedic and neurosurgical procedures. Globus Medical and Stereotaxis’ robotic portfolios include ExcelsiusGPS and Genesis systems, respectively, used for spine and cranial procedures, and endovascular interventions. The underperformance of the ISRG stock has led to a decline in its valuation multiples as well. The Price-to-Earnings Forward 12 Month (P/E F12M) valuation has fallen from a high of 96.05X at the beginning of 2025 to its current 37.12X, reflecting a significant decline despite robust earnings growth. At its current valuation multiples, the ISRG stock looks attractive amid its strong fundamentals. P/E F12M Valuation of ISRG vs Industry Image Source: Zacks Investment Research Despite consistently delivering double-digit revenue and earnings growth, Intuitive Surgical stock has remained under pressure this year as investors weigh near-term margin headwinds against its long-term growth story. The biggest concern stems from the ongoing rollout of the next-generation da Vinci 5 platform. Although customer adoption has exceeded expectations, the system currently carries lower margins...

Globus Medical, Inc. (NYSE:GMED) is one of the cheap robotics stocks to buy right now. On May 18, Citizens reiterated a Market Perform rating on Globus Medical (NYSE:GMED) on first-quarter results exceeding expectations. The impressive results were characterized by 27% overall revenue growth and record earnings. Organic revenue was up 13%, driven by share gains and procedural volume strength in core spine. Consequently, worldwide revenues totaled $759.9 million, as base business net sales excluding Nevro totaled $677.2 million. Robust revenue growth came as Globus Medical’s Musculoskeletal Solutions and Enabling Tech segments achieved broad-based growth in the quarter. Revenue in the Spine channel was up 10%, marking the third consecutive quarter of 10% growth. Net income in the quarter totaled $124.3 million as diluted earnings per share increased 64.7% to $1.12. Earnings beat estimates by 22%, driven by higher sales. International Spine revenue was also up by 10%. For the full year, Globus Medical expects revenue to range between $3.18 billion and $3.33 billion. It has also updated its non-GAAP diluted EPS to between $4.70 and $4.80, up from the previous guidance of $4.40 to $4.50. Globus Medical, Inc. (NYSE:GMED) develops advanced surgical robotics and navigation platforms designed to improve the accuracy, safety, and efficiency of orthopedic, spinal, and cranial procedures. Their technology acts as a “third hand” for surgeons, combining rigid robotic arms with real-time tracking. While we acknowledge the potential of GMED as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Sin Stocks to Buy Now and 8 Best CBD Stocks to Buy Right Now. Disclosure: None. Follow Insider Monkey on Google News.

The Cooper Companies, Inc. COO posted second-quarter fiscal 2026 adjusted earnings per share (EPS) of $1.21, up 26.0% year over year and beat the Zacks Consensus Estimate of $1.10 by 10.0%. Operational improvements have driven bottom-line growth. GAAP loss per share for the quarter was 40 cents, significantly down from the year-ago period’s GAAP EPS of 44 cents, affected by a litigation-related charge tied to the resolution of claims associated with a December 2023 voluntary product recall at CooperSurgical. Revenues totaled $1.08 billion, up 8% year over year on a reported basis and up 5% organically. The figure topped the Zacks Consensus Estimate of $1.05 billion by 2.6%. The quarterly revenues were up 5% year over year at constant exchange rate (CER). The top-line growth was driven by steady demand across CooperVision and CooperSurgical, alongside new product launches and continued operating discipline. Shares of COO were up 5.3% in after-hours trading following the earnings call. The company’s shares have lost 24.3% in the year-to-date period compared with the industry’s 10.4% decline. However, the S&P 500 Index was up 10.3% during the same period. Image Source: Zacks Investment Research COO conducts its business via two reportable segments — CooperVision (“CVI”) and CooperSurgical (“CSI”). COO delivered record quarterly revenues as both operating segments contributed to growth. For the second quarter of fiscal 2026, the CVI segment’s revenues totaled $723.5 million, up 8% year over year on a reported basis and 4% at CER as well as organically. This figure compares to our segmental projection of $711 million. Growth was supported by strong sales of MyDay and MiSight, combined with rising sales of Biofinity, torics and multifocals. MyDay lenses continued its double-digit growth rate. Biofinity grew 5% organically, while MiSight delivered strong growth of 24%. However, softness in Clariti lens sales continued in the fiscal second quarter as the global contact lens market continues to trend toward premium offerings, which included MyDay offerings. Category-wise, CVI derives revenues from Toric and multifocal, Sphere and others. In the fiscal second quarter, Toric and multifocal revenues totaled $364.9 million, up 11% year over year on a reported basis, and up 7% organically as well as at CER. This figure compares to our projection of $355 million. Sphere an...

Veeva Systems, Inc. VEEV reported adjusted earnings per share (EPS) of $2.24 for the first quarter of fiscal 2027, which increased 13.7% from the year-ago figure of $1.74. Adjusted EPS beat the Zacks Consensus Estimate by 5.2%. GAAP EPS in the fiscal first quarter was $1.57, up 14.6% from the year-ago period’s $1.37. In the quarter under review, the company’s revenues totaled $882.9 million, beating the Zacks Consensus Estimate by 2.9%. On a year-over-year basis, the top line improved 16.3%. However, shares of the company lost 5.2% in yesterday’s after-market trading. The stock lost 19.8% in the year-to-date period compared with the industry’s decline of 19.1%. However, the S&P 500 Index has increased 10.2% in the same time frame. The fiscal first-quarter top line was driven by Veeva Systems’ robust segmental performance. Image Source: Zacks Investment Research Veeva Systems derives revenues from two operating segments: Subscription services and Professional services and other. In the fiscal first quarter, Subscription services revenues improved 15% from the year-ago quarter to $730.2 million. Per management, this uptick was driven by both its established and newer solutions. Professional services and other revenues increased 22.9% year over year to $152.8 million. In the quarter under review, Veeva Systems’ gross profit improved 13.1% year over year to $662 million. However, the gross margin contracted 220 basis points (bps) to 74.9%. Sales and marketing expenses increased 12.7% year over year to $111.1 million. Research and development (R&D) expenses rose 13.2% year over year to $208.3 million, while general and administrative expenses increased 0.9% year over year to $69.5 million. Total operating expenses of $388.9 million increased 10.6% year over year. Operating profit totaled $273.1 million, which increased 16.8% from the prior-year quarter. The operating margin in the fiscal first quarter expanded 20 bps to 30.9%. The company exited first-quarter fiscal 2027 with cash and cash equivalents and short-term investments of $7.31 billion compared with $6.56 billion at the fiscal fourth quarter of 2026-end. Net cash provided by operating activities at the end of the quarter was $1.13 billion compared with $877.2 million a year ago. Veeva Systems has issued its financial outlook for the fiscal second quarter and fiscal 2027. For the fiscal second quarter, th...

HealthEquity, Inc. HQY reported adjusted earnings per share (EPS) of $1.24 for first-quarter fiscal 2027, surpassing the Zacks Consensus Estimate by 11.7%. The bottom line improved 28% on a year-over-year basis. GAAP EPS in the fiscal first quarter was 82 cents, up from the year-ago quarter’s EPS of 61 cents. Shares of HQY gained 1.04% in after-market trading following the earnings call. In the fiscal first quarter, the company generated revenues of $354.6 million, which beat the Zacks Consensus Estimate by 0.06%. The top line improved 7% from the prior-year quarter. As of April 30, 2026, the total number of Health Savings Accounts (HSAs) for which HealthEquity served as a non-bank custodian was 10.6 million, up 8% year over year. HealthEquity reported 909,000 HSAs with investments as of April 30, 2026, up 18% year over year. Total accounts, as of April 30, 2026, were 17.8 million. This uptick included total HSAs and 7.2 million Consumer Direct Benefits (CDBs). Total HSA assets were $37.1 billion at the end of April 30, 2026, up 19% year over year. This included $17.5 billion of HSA cash and $19.6 billion of HSA investments. This figure compares to our fiscal first-quarter HSA cash and HSA investments projection of $17.6 billion and $17.9 billion, respectively. We had projected total HSA assets of $35.5 billion for the fiscal first quarter. Client-held funds, which are deposits held on behalf of HealthEquity’s clients to facilitate the administration of its CDBs and from which the company generates custodial revenues, were $1.0 billion as of April 30, 2026. HealthEquity derives revenues from three sources: Service revenues, Custodial revenues and Interchange revenues. Service revenues totaled $122.9 million in the quarter, up 2.6% year over year. This reflected a higher number of HSAs and invested HSA Assets. This figure compares favorably with our fiscal first-quarter projection of $122 million. Custodial revenues totaled $174.3 million, up 11.4% from the year-ago period. Our projection for the fiscal first-quarter Custodial revenues was $176 million. Interchange revenues totaled $57.4 million, up 5.1% year over year. This figure compares favorably with our fiscal first-quarter projection of $58 million. HealthEquity, Inc. price-consensus-eps-surprise-chart | HealthEquity, Inc. Quote In the quarter under review, HealthEquity’s gross profit rose 14.3% year o...

Auna AUNA posted first-quarter 2026 adjusted earnings per share (EPS) of 5 cents, which missed the Zacks Consensus Estimate by 73%. The adjusted figure also decreased 73.7% year over year. GAAP EPS was 3 cents compared with 13 cents in the year-ago period. Revenues of $337 billion increased 18.7% year over year. The figure surpassed the Zacks Consensus Estimate by 2.4%. Following the announcement, shares of AUNA fell 2.7% in after-market trading yesterday. The fall was due to investors’ concern over declining EPS during the quarter. The company currently has four reportable segments— Oncosalud Peru, Healthcare services in Peru, Healthcare services in Colombia and Healthcare services in Mexico. Sales in the Oncosalud Peru segment improved 12% year over year to $90 million. Healthcare services in Peru sales grew 7% year over year to $81 million. Revenues in the Healthcare services in Colombia segment rose 18% year over year to $114 million. Healthcare services in Mexico revenues rose 15% to $80 million in the first quarter. Adjusted gross margin was 36.5%, reflecting a contraction of 12 basis points (bps) year over year. Gross margin contracted due to an 18.9% rise in the cost of sales and services. Selling expenses rose 20% to $18 million. Administrative expenses rose 22% to $61 million. Adjusted operating margin contracted 68 bps to 13.1%. Auna exited the first quarter of 2026 with cash and cash equivalents of $117 million compared with $100 million at the end of the fourth quarter of 2025. Cumulative net cash provided by operating activities at the end of the first quarter was $50 million compared with $29 million in the year-ago period. Auna S.A. price-consensus-eps-surprise-chart | Auna S.A. Quote Auna reaffirmed its guidance for 2026. The company expects revenue growth of 12% FXN, within a range of 10% to 14%. The Zacks Consensus Estimate for revenues is pegged at $1.39 billion, implying 11.1% year-over-year growth. Adjusted EBITDA is expected to grow 12% FXN, within a range of 10% to 14%. Auna exited the first quarter on a mixed note, with earnings missing estimates and revenues beating the same. Peru continues to show significant growth potential in Healthcare plans, with initiatives underway to offset revenue adjustments as the Trecca ambulatory tower progresses toward completion. Colombia is performing strongly, supported by a more balanced payor bas...

NeuroPace NPCE delivered a first-quarter 2026 adjusted loss per share of 13 cents compared with an adjusted loss of 18 cents in the year-ago period. The figure was 31.6% narrower than the Zacks Consensus Estimate. GAAP loss per share for the quarter was 20 cents compared with 21 cents in the year-ago period. NeuroPace registered revenues of $22.1 million in the first quarter, down 2% year over year, reflecting strong RNS System sales of $21.7 million (up 19.5% year over year) alongside $314,000 in service revenues and $0.1 million from DIXI Medical wind-down. The figure surpassed the Zacks Consensus Estimate by 2.07%. Shares of NPCE were up approximately 0.2% during after-market trading following the first-quarter results. The company’s shares have gained 2.3% in the year-to-date period against the industry’s decline of 20.1%. The broader S&P 500 Index has increased 9% in the same time frame. Image Source: Zacks Investment Research In the quarter under review, NeuroPace’s adjusted gross profit increased 18.6% year over year to $18.1 million. Adjusted gross margin contracted 110 basis points (bps) to 82.5%. Sales and marketing expenses increased 5.3% year over year to $11.6 million, research and development expenses decreased 3.4% year over year to $7.2 million and general and administrative expenses increased 19.7% year over year to $4.8 million. Adjusted operating expenses of $21.5 million rose 10.5% year over year. The adjusted operating loss totaled $3.3 million, down from $4.1 million in the prior-year quarter. NeuroPace ended first-quarter 2026 with total cash, cash equivalents and short-term investments of $53.9 million, compared with $61.1 million at the end of fourth-quarter 2025. Cumulative net cash used in operating activities at the end of first-quarter 2026 was $5.9 million compared with $7.5 million a year ago. NeuroPace has raised its outlook for the full year 2026. For 2026, management provided total revenue guidance of $99 million-$101 million (up from $98 million to $100 million previously) on a continuing-operations basis, with RNS growth of 21%-23%, compared to full year 2025. The Zacks Consensus Estimate is pegged at $98.8 million. The adjusted gross margin is expected to be at 81.5%-82.5%, supported by ongoing pricing discipline and manufacturing efficiencies. Adjusted operating expenses are guided to $90 million-$92million, excluding ap...

Doximity, Inc. DOCS delivered adjusted earnings per share (EPS) of 26 cents in the fourth quarter of fiscal 2026, down 31.6% year over year. The figure missed the Zacks Consensus Estimate by 7.1%. GAAP EPS for the quarter was 10 cents, reflecting a downtick of 67.7% from the year-ago figure. Adjusted EPS for fiscal 2026 was $1.52, up 7% year over year. GAAP EPS for fiscal 2026 was 98 cents, down 11.7% year over year. Doximity registered revenues of $145.4 million in the fiscal fourth quarter, up 5% year over year. The figure surpassed the Zacks Consensus Estimate by 1.2%. The revenue growth was driven by stronger spending from existing customers, reflected in a 109% net revenue retention rate and growth in large accounts, with 125 customers contributing over $500,000 in subscription-based revenues and representing 83% of revenues. Total revenues for fiscal 2026 were $644.9 million, up 13% year over year. Following the earnings release, shares of DOCS fell 19.3% in after-hours trading yesterday. The company’s shares have lost 47.2% in the year-to-date period compared with the industry’s decline of 23%. However, the broader S&P 500 Index has increased 8.7% in the same time frame. Image Source: Zacks Investment Research In the quarter under review, Doximity’s adjusted gross profit rose 2.7% year over year to $129.9 million. However, the adjusted gross margin contracted 210 basis points (bps) to 89.3%. Sales and marketing expenses increased 22.1% year over year to $45.9 million, and research and development expenses rose 57.7% year over year to $39.1 million. General and administrative expenses increased 26.7% year over year to $16.1 million. Total operating expenses of $101.1 million rose 34.6% year over year. The adjusted operating profit totaled $63.6 million, reflecting a 6.4% downtick from the prior-year quarter. The adjusted operating margin in the fiscal fourth quarter contracted 530 bps to 43.8%. Doximity exited fourth-quarter fiscal 2026 with cash and cash equivalents of $219.2 million compared with $64.8 million at the fiscal third-quarter end. Cumulative net cash provided by operating activities at the end of fourth-quarter fiscal 2026 was $109.5 million compared with $98.5 million a year ago. Doximity has provided its financial outlook for the fiscal first quarter and the full year of fiscal 2027. For the fiscal first quarter, the company expects rev...

Globus Medical (GMED) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.68 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +22.07%. A quarter ago, it was expected that this medical device company would post earnings of $1.06 per share when it actually produced earnings of $1.28, delivering a surprise of +20.75%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Globus Medical, which belongs to the Zacks Medical - Instruments industry, posted revenues of $759.85 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 4.04%. This compares to year-ago revenues of $598.12 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Globus Medical shares have added about 2.2% since the beginning of the year versus the S&P 500's gain of 7.6%. While Globus Medical has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Globus Medical was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #1 (Strong Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of to...

AUDUBON, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the first quarter ended March 31, 2026. First Quarter 2026: Worldwide net sales were $759.9 million, an increase of 27.0%, or an increase of 25.5% on a constant currency basis. Base business, excluding Nevro, net sales were $677.2 million, an increase of 13.2%, or an increase of 11.2% on a constant currency basis. GAAP net income for the quarter was $124.3 million. GAAP diluted earnings per share (“EPS”) was $0.90, an increase of 66.6%. Non-GAAP diluted EPS was $1.12, an increase of 64.7%. “We’re off to a strong start in 2026 with 27% overall revenue growth and record first quarter earnings. Organic revenue grew over 13%, driven by share gains and procedural volume strength in core spine, while Enabling Technologies delivered against its pipeline and continued to expand its customer base,” commented Keith Pfeil, President and Chief Executive Officer. “Disciplined execution on manufacturing and supply chain initiatives, as well as structural cost actions, coupled with operating leverage on higher volumes, drove margin expansion in excess of sales growth, which we expect to favorably impact full-year results. Our strategic priority remains centered on achieving improved surgical outcomes through the Globus ecosystem, bringing together patient selection, surgical techniques with complementary implants and technology to drive the surgical procedure, through a closed-loop surgical intelligence system.” “In the first quarter, US Spine continued to lead the way in growth for the organization, posting the third straight 10% growth quarter when compared to the same quarter of the prior year. This, paired with growth across all of our significant underlying businesses, drove record first quarter GAAP and non-GAAP net income and diluted earnings per share,” said Kyle Kline, Chief Financial Officer. “Nevro performed as expected as we continue to diligently work through the integration and adapt the business to Globus’ systems, processes, and metrics. Our total Company first quarter results represent an impressive beginning to 2026, reflecting the ongoing benefits of operating leverage, synergy realization, and financial discipline, positioning us well to deliver sustained earnings growth and value creat...

Image source: The Motley Fool. Thursday, May 7, 2026 at 4:30 p.m. ET President and Chief Executive Officer — Keith W. Pfeil Chief Financial Officer — Kyle Kline Vice President, Investor Relations — Brian Kearns Need a quote from a Motley Fool analyst? Email [email protected] Brian Kearns: Thank you, Kathy, and thank you, everyone, for being with us today. Joining today's call from Globus Medical, Inc. will be Keith W. Pfeil, President and CEO, and Kyle Kline, Chief Financial Officer. This review is being made available via webcast accessible through the Investor Relations section of the Globus Medical, Inc. website at www.globusmedical.com. Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements. Our Form 10-Ks for the 2025 fiscal year and our subsequent filings with the Securities and Exchange Commission identify certain factors that could cause our actual results to differ materially from those projected in any forward-looking statements made today. Our SEC filings, including the 10-Ks, are available on our website. We do not undertake to update any forward-looking statements as a result of new information or future events or developments. Our discussion today will also include certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We believe these non-GAAP financial measures provide additional information pertinent to our business performance. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most directly comparable GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are available in the schedules accompanying the press release and on the Investor Relations section of the Globus Medical, Inc. website. With that, I will now turn the call over to Keith W. Pfeil, our President and CEO. Keith W. Pfeil: Thanks, Brian. Good afternoon, everyone, and thank you for joining us on today's call. Our first quarter results demonstrate our ongoing focus as we continue to scale and capture share while maintaining operational discipline, driving margin expansion, favorably impacting Q1 and our full-year results looking ahead. Overall, we are moving with purpose and in the right direction. As we progress through 2026, look for market...